Hamlet BioPharma AB publ (XSAT:HAMLET B) Total Current Liabilities: kr5.69 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:HAMLET B Hamlet BioPharma AB publ XSAT:HAMLET B
31 GF Score
Price kr6.67
! 2 Warning Signs
View Full Analysis

What is Hamlet BioPharma AB publ Total Current Liabilities?

Hamlet BioPharma AB publ XSAT:HAMLET B -1.91% 31 Total Current Liabilities is kr5.69 Mil as of Mar. 2026. GuruFocus rates XSAT:HAMLET B with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Hamlet BioPharma AB publ's total current liabilities for the quarter that ended in Mar. 2026 was kr5.69

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Hamlet BioPharma AB publ Total Current Liabilities Related Terms

Hamlet BioPharma AB publ Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Hamlet BioPharma AB publ's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hamlet BioPharma AB publ Total Current Liabilities Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.99 3.72 2.55 4.11 7.27

Hamlet BioPharma AB publ Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.76 7.27 4.84 7.59 5.69
XSAT:HAMLET B
31GF Score
Hamlet BioPharma AB publ XSAT:HAMLET B
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hamlet BioPharma AB publ Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Hamlet BioPharma AB publ's Total Current Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.053+0
+Other Current Liabilities+Current Deferred Liabilities
=4.213+0
=7.27

Hamlet BioPharma AB publ's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.337+0
+Other Current Liabilities+Current Deferred Liabilities
=2.356+0
=5.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of kr5.69 Mil mean?
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a Total Current Liabilities of kr5.69 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Hamlet BioPharma AB publ and its competitors.
Is Hamlet BioPharma AB publ's Total Current Liabilities too high?
Hamlet BioPharma AB publ's current Total Current Liabilities is kr5.69 Mil. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's Total Current Liabilities compare to VRTX and REGN?
Hamlet BioPharma AB publ's Total Current Liabilities of kr5.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Hamlet BioPharma AB publ and its competitors. Hamlet BioPharma AB publ's current Total Current Liabilities is kr5.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a current Total Current Liabilities of kr5.69 Mil. The current Total Current Liabilities is kr5.69 Mil. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Hamlet BioPharma AB publ (XSAT:HAMLET B), the current Total Current Liabilities is kr5.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hamlet BioPharma AB publ Business Description

Other Exchanges 7ZT:Germany
Address Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
31GF Score

Get the complete analysis for XSAT:HAMLET B

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.67
Price